AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (June 2016)

36 slides from AVEO Pharmaceuticals's investor presentation, Jun 15, 2016

  1. Slide 1: AVEO Overview June 2016

    AVEO Overview June 2016 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”

  3. Slide 3: Retained North American Rights for Oncology Portfolio While Leveraging Partnerships

    Retained North American Rights for Oncology Portfolio While Leveraging Partnerships to Advance Our Pipeline AV-380 GDF15 MAb Tivozanib VEGF 123 TKI (Oncology Indications) AV-203 ERBB3 MAb Ficlatuzumab HGF MAb Value Creation Strategy Leverage partner resources to advance development, retain significa

  4. Slide 4: Partnerships Provide Significant Downstream Value Potential, Support for North American Strategy

    Partnerships Provide Significant Downstream Value Potential, Support for North American Strategy Tivozanib EU, Other December 2015 Tivozanib Ocular November 2014 AV-380 August 2015 Ficlatuzumab April 2014 Potential for ~$1 Billion in partnership payments plus meaningful royalties AV-203 March 2016

  5. Slide 5: Multiple Opportunities for Value Creation

    TIVO-1 (1st Line RCC) * Ocular Serum Proteomic Biomarker NSCLC NRG-1 Biomarker Solid Tumors Cachexia U.S. Phase 3 Registration Study in RCC PD-1 RCC PAH Multiple Opportunities for Value Creation *Filed in EU by EUSA FEB 29, 2016, validated MAR 23, 2016 Seeking Partnership

  6. Slide 6: Tivozanib

    Tivozanib A potent, selective, long half-life inhibitor of vascular endothelial growth factor (VEGF) 1, 2 and 3 receptors

  7. Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:

  8. Slide 8: Large and Growing RCC Opportunity

    Large and Growing RCC Opportunity ~$1.5 Billion ~$1.0 Billion Market opportunity currently ~$2.5 billion in Europe and North America* Future market needs: Improved tolerability Increased efficacy through combinations with immunotherapy * Total RCC market includes all stages of disease and treatment

  9. Slide 9: Tivozanib RCC Potential development and registration scenarios

    Tivozanib RCC Potential development and registration scenarios MAA Review TIVO-3 – Tivo v. Sorafenib US Approval Decision EU Approval Decision NDA Review 2016 2017 2018 2019 2020 Ph 2 expansion or Ph 3 Trial of Tivo + PD-1 Ph 1/2 Tivo + PD-1 Potential NDA Filing 2H 2018 PFS Data/OS Trend Estimated 1

  10. Slide 10: Tivozanib RCC Front-line Setting

    Tivozanib RCC Front-line Setting

  11. Slide 11: TIVO-1: Proven Activity in 1st line RCC

    Phase 3 TIVO-1: Proven Activity in 1st line RCC 517 patient, global, randomized Phase 3 in 1st line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; NDA not approved; FDA requested additional study Demonstrated favorable tolerability profi

  12. Slide 12: Comparable OS Despite Limited Subsequent Therapy

    Comparable OS Despite Limited Subsequent Therapy

  13. Slide 13: Support for Tivozanib MAA Filing for RCC: Impact of Next-Line Therapy on OS

    Support for Tivozanib MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study

  14. Slide 14: EUSA Pharma Oncology Licensing Agreement

    EUSA Pharma Oncology Licensing Agreement EU filing 2/29/16, validated 3/23/16 >$396M in Upfront and Potential Milestones $16M potential 2016/17 milestones* Tiered royalties from low double digits to mid twenties Milestone and royalty payments subject to the successful development or commercializatio

  15. Slide 15: Favorable Tolerability vs. Approved TKIs in RCC

    Favorable Tolerability vs. Approved TKIs in RCC 1. AVEO Data on file; 2. INLYTA prescribing information v.01.2012; 3.Votrient prescribing information revised 01.2012; 4. Sutent prescribing information revised 05.2011; 5. Cabozantinib METEOR Trial NEJM 9.2015; 6. Lenvatinib USPI Dose Reductions: Cabo

  16. Slide 16: Tivozanib is Well Tolerated, Potential Preferred TKI for PD1 Combination Therapy

    Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for PD1 Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta3 (n=359) Nexavar4 (n=257) Cometriq2 (n=331) Lenvatinib5 + Everolimus Tivozanib4 (n=259) Hypertension 30% (15%)

  17. Slide 17: Top Three Toxicities Relevant to Patients with Advanced RCC

    Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and

  18. Slide 18: Tivozanib North American Registration Strategy

    Tivozanib North American Registration Strategy

  19. Slide 19: TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC

    TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and tolerability for ITT & Pre-Speci

  20. Slide 20: Tivozanib Efficacy in VEGF TKI Refractory Setting

    Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS ^Cabozantanib USPI Motzer et al Lancet Oncol 2013; 14: 552–62 Motzer et al Lancet Oncol 2014 Hutson et al ASCO 2015 Motzer ESMO

  21. Slide 21: Tivozanib PD-1 Combination Setting

    Tivozanib PD-1 Combination Setting

  22. Slide 22: Rationale for combining VEGF + PD-(L)1 inhibitors

    Rationale for combining VEGF + PD-(L)1 inhibitors Gunturi, McDermoot Current Treatment Options in Oncology 2014 Pilmack International Kidney Cancer Symposium 2014

  23. Slide 23: Tivozanib Properties Favorable for PD-1 Combination

    Tivozanib Properties Favorable for PD-1 Combination Pawlowski N et al. AACR 2013. Poster 3971.

  24. Slide 24: Early Data for Axitinib + Pembrolizumab: Promising Efficacy, Challenging Toxicity

    Early Data for the Combination of Axitinib + Pembrolizumab: Demonstrated Promising Efficacy, Challenging Toxicity Atkins et al, SITC 2015 *Selected AEs include all with Grade 3/4 Three DLTs reported: transient ischemic attack (TIA; n=1) and < 75% of planned axitinib dose received due to treatment-re

  25. Slide 25: Toxicity in Select TKI Combinations with PD-1s

    Toxicity in Select TKI Combinations with PD-1s Courtesy of Dr. S. Pal, ASCO GU 2015

  26. Slide 26: Comparison of Liver AEs in TKIs

    Axitinib Tivozanib Axitinib Tivozanib Comparison of Liver AEs in TKIs Liver AEs are significantly higher for sutent, pazopanib and axitinib, compared to tivozanib When TKIs and PD1s are combined, the increase in Grade 3/4 AEs is more than additive When combined with PD1, Grade 1/2 AEs appear to be a

  27. Slide 27: Robust Pipeline Development Funded by Partnerships

    Robust Pipeline Development Funded by Partnerships

  28. Slide 28: Tivozanib: Non-Oncology Exclusive License Agreement

    Tivozanib: Non-Oncology Exclusive License Agreement >$105M total in upfront and potential option & milestone payments Potential for $10M in 2016 Tiered, double digit royalties, up to the mid-teens, on net sales* Figures from Ophthotech R&D Investor Day Dec 3, 2015 Option, milestone and royalty payme

  29. Slide 29: Advancing Robust Pipeline Through Partnership

    Advancing Robust Pipeline Through Partnership Milestone and royalty payments subject to the successful development and/or commercialization of the product *A percentage of proceeds will be shared with SVH, including of $1.5 million of upfront AV-380 (GDF-15 inhibitor MAb) Indication: Cachexia Incide

  30. Slide 30: AV-353: First-in-Class Opportunity in Pulmonary Arterial Hypertension

    AV-353: 1st-in-class opportunity to address major unmet need in Pulmonary arterial hypertension (PAH) as first drug with disease modifying properties Binding specificity to Notch 3 reduces risks of pan-Notch toxicities that have hampered competitors Large Market Opportunity 2014 sales of $3.45B à 20

  31. Slide 31: Financials & Summary

    Financials & Summary

  32. Slide 32: Financial Highlights

    Financial Highlights Cash and anticipated operational milestones to fully fund North American tivozanib development strategy to topline data $24M in cash and investments as of 1Q 2016 $17M equity financing completed 2Q 2016 Amended debt agreement for additional $5M, access to another $5M tranche and

  33. Slide 33: Significant Progress During 2015 and 2016

    Significant Progress During 2015 and 2016 Tivozanib Initiation of 3rd line confirmatory RCC Phase 3 study Filing and acceptance of filings in EU Partnership in EU ASCO presentation of refractory RCC data Presentation of encouraging CRC data Pipeline AV-380 partnership and option exercise AV-203 part

  34. Slide 34: Potential Corporate Milestones

    Potential Corporate Milestones Tivozanib Regulatory decision in EU (1Q17) Other geographic partnerships Initiation of PD1 combination study Proof of concept in AMD and option exercise (2016/17) TIVO-3 PFS data/OS trend (1Q18) Potential NDA submission (2H18) Pipeline (2016/17) Partnership for AV-353

  35. Slide 35: AVEO Oncology Highlights

    AVEO Oncology Highlights Retained significant North American (N.A.) rights for all oncology therapeutic assets Executing on potential N.A. registration strategies for Tivozanib Enrolling Ph 3 refractory RCC study (TIVO-3) to support 1st & 3rd line indications Anticipated PD1 combination study in RCC

  36. Slide 36: AVEO Overview June 2016

    AVEO Overview June 2016

AVEO Pharmaceuticals — Investor Presentation (June 2016) on 6ix